Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-104042
Filing Date
2025-08-06
Accepted
2025-08-06 16:13:17
Documents
69
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q algs-20250630.htm   iXBRL 10-Q 3089124
2 EX-10.3 algs-ex10_3.htm EX-10.3 94586
3 EX-31.1 algs-ex31_1.htm EX-31.1 18439
4 EX-31.2 algs-ex31_2.htm EX-31.2 18484
5 EX-32.1 algs-ex32_1.htm EX-32.1 10702
6 EX-32.2 algs-ex32_2.htm EX-32.2 10742
  Complete submission text file 0000950170-25-104042.txt   9751079

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT algs-20250630.xsd EX-101.SCH 1199835
72 EXTRACTED XBRL INSTANCE DOCUMENT algs-20250630_htm.xml XML 1647645
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39617 | Film No.: 251189726
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)